{"schema_version":"secwatch.filing_event.v1","accession":"0001279569-24-000603","form_type":"8-K","ticker":null,"cik":"0001633932","company_name":"ESSA Pharma Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.339181+00:00","generated_at":"2026-06-02T00:52:12.929230+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ESSA Pharma Q2 net loss $9.0M; Phase 1 masofaniten combo shows 81% PSA90 in mCRPC","bullets":["Net loss $9.0M (Q2 2024) vs $7.1M (Q2 2023); R&D expense $6.2M; cash $135.9M, sufficient beyond 2025.","Phase 1 masofaniten+enzalutamide: 81% PSA90, 69% within 90 days, 63% PSA<0.2 ng/mL; median PSA progression 16.6 months.","Phase 2 enrollment completion expected Q1 2025; preliminary data mid-2025; ~25 sites active, 15 European sites by Q3 2024.","Additional arms enrolling: masofaniten+abiraterone/prednisone and +apalutamide; Phase 1b monotherapy results H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001279569-24-000603","json":"https://secwatch.observer/filing/0001279569-24-000603.json","markdown":"https://secwatch.observer/filing/0001279569-24-000603.md","text":"https://secwatch.observer/filing/0001279569-24-000603.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1633932/000127956924000603/0001279569-24-000603-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1633932/000127956924000603/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:52:12.929230+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"00ea7d67588c3376b80302d8e857964083e514c0","claim":"ESSA Pharma Inc. reported fiscal second quarter ended March 31, 2024 results: net income $9.0 million.","evidence_excerpt":"Net Loss. ESSA recorded a net loss of $9.0 million for the second quarter ended March 31, 2024 compared to $7.1 million for the second quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1633932/000127956924000603/0001279569-24-000603-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal second quarter ended March 31, 2024"},{"label":"Net income","value":"$9.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}